Pneumococcal vaccine delivery in the biotherapy population
Birebent, Jordan
Pneumococcal vaccine delivery in the biotherapy population - 2023.
33
Chronic inflammatory digestive or rheumatological pathologies are a risk factor for the development of infectious pathologies, particularly respiratory ones. For patients receiving biotherapies, the risk of pneumonia doubles. Prevenar 13® obtained Marketing Authorization for this indication in July 2013, with the HCSP publishing a new recommendation in December 2014, taking into account the fact that this marketing authorization had been obtained. This study aimed primarily to evaluate pneumococcal vaccination coverage in the French population treated with TNF-alpha inhibitors.
Pneumococcal vaccine delivery in the biotherapy population - 2023.
33
Chronic inflammatory digestive or rheumatological pathologies are a risk factor for the development of infectious pathologies, particularly respiratory ones. For patients receiving biotherapies, the risk of pneumonia doubles. Prevenar 13® obtained Marketing Authorization for this indication in July 2013, with the HCSP publishing a new recommendation in December 2014, taking into account the fact that this marketing authorization had been obtained. This study aimed primarily to evaluate pneumococcal vaccination coverage in the French population treated with TNF-alpha inhibitors.
Réseaux sociaux